GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.
The first two respiratory syncytial virus (RSV) vaccines for older people, GSK’s Arexvy and Pfizer’s Abrysvo have been recommended by a key US panel, but reservations its experts expressed about the products will present a barrier for uptake.
One key issue was price and cost effectiveness, as neither company was willing to provide a definitive price for their...
The CAR-T specialist is spending $350m to acquire the private Philadelphia-based firm, which is developing in vivo CAR-Ts using lentiviral vectors.
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.
